Top Markets
Coin of the day
Cyxone AB (publ) Cyxone AB (publ)

Cyxone AB (publ)

CYXO
株式のランク #40403
Cyxone AB (publ) is a clinical-stage biotechnology firm focused on developing... Cyxone AB (publ) is a clinical-stage biotechnology firm focused on developing innovative, disease-modifying therapies. Its primary therapeutic targets include rheumatoid arthritis, multiple sclerosis, and acute respiratory illnesses caused by viruses. The company's pipeline features Rabeximod, currently in Phase II clinical trials for both rheumatoid arthritis and COVID-19. Additionally, T20K, a drug candidate for multiple sclerosis, is undergoing Phase 1 evaluation. Established in 2015, the company is headquartered in Malmö, Sweden.
株価
$0.00162013
最終同期: 2025-01-03
時価総額
$156.25K
変化(1日)
0.36%
変化(1年)
0.00%
SE
取引 Cyxone AB (publ) (CYXO)

カテゴリー

Cyxone AB (publ)(CYXO)のEPS
June 2024 時点のEPS TTM: $-0.01
Cyxone AB (publ)の最新の財務報告と株価によると、同社の現在のEPS(TTM)は$-0.01です。2022年末には、EPSは$-0.04で、2021年のEPS$-0.08と減少でした。
Cyxone AB (publ)のEPS履歴(2015から2026まで)
各年末時点のEPS
EPS 変化
2026 (TTM) $-0.01 -29.00%
2023 $-0.02 -48.34%
2022 $-0.04 -47.71%
2021 $-0.08 -15.59%
2020 $-0.10 13.00%
2019 $-0.08 88.84%
2018 $-0.04 -16.73%
2017 $-0.05 88.11%
2016 $-0.03 2,100.00%
2015 0.00 0.00%
同様の企業または競合他社のEPS
企業 EPS EPSの差
$17.32 -122,071.83%
US
$27.74 -195,452.11%
NL
- -
CH
- -
KR
$13.70 -96,579.58%
BE